Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Year: 2024
Type: other
Abstract: Figure S10: Acquired resistance to the combination of LB-100 and Adavosertib suppress anchorage-independent and tumor growth in CRC models (A) Endpoint proliferation of HT-29 and SW-480 parental and resistant cells growing attached or in anchorage-independent conditions. Cells were plated in the same density on regular or cell-repellent culture plates in the absence of drugs and grown for 5-6 days. Proliferation was addressed by CellTiter-Glo 3D® and is expressed as fold change over T0. (B) Growth curves of the individual tumors from SW-480 parental and resistant cells measured 3 times per week. The dashed line indicates the 1500 mm3 ethical sacrifice.
Authors: Matheus Henrique Dias, Anoek Friskes, Siying Wang, Joao M. Fernandes Neto, Frank van Gemert, Soufiane Mourragui, Chrysa Papagianni, Hendrik J. Kuiken, Sara Mainardi, Daniel Alvarez-Villanueva, Cor Lieftink, Ben Morris, Anna Dekker, Emma van Dijk, Lieke H.S. Wilms, Marcelo S. da Silva, Robin A. Jansen, Antonio Mulero-Sánchez, Elke Malzer, August Vidal, Cristina Santos, Ramón Salazar, Rosangela A.M. Wailemann, Thompson E.P. Torres, Giulia De Conti, Jonne A. Raaijmakers, Petur Snaebjornsson, Shengxian Yuan, Wenxin Qin, John S. Kovach, Hugo A. Armelin, Hein te Riele, Alexander van Oudenaarden, Haojie Jin, Roderick L. Beijersbergen, Alberto Villanueva, Rene H. Medema, Rene Bernards
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4400214397